Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MODIFI: Model-informed Infliximab Dose De-escalation in IBD
NCT04982172Phase 4Completed
- Sponsor
- UZ Leuven
- Start
- Feb 2022
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of infliximab in ulcerative colitis (UC), Crohn's disease, sponsored by UZ Leuven. Started Feb 2022; status: completed.
02
Drugs
infliximab
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT04982172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04982172.